FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198126629> ?p ?o ?g. }

• W3198126629 endingPage "1853" @default.
• W3198126629 startingPage "1844" @default.
• W3198126629 abstract "Pyruvate kinase deficiency (PKD) is the most common cause of congenital nonspherocytic hemolytic anemia. Although recognition of the disease spectrum has recently expanded, data describing its impact on health-related quality of life (HRQoL) are limited. In this prospective international cohort of 254 patients (131 adults and 123 children) with PKD, we used validated measures to assess the impact of disease on HRQoL (EuroQol 5-Dimension Questionnaire, Pediatric Quality of Life Inventory Generic Core Scale version 4.0, and Functional Assessment of Cancer Therapy-Anemia) and fatigue (Patient Reported Outcomes Measurement Information System Fatigue and Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue). Significant variability in HRQoL and fatigue was reported for adults and children, although individual scores were stable over a 2-year interval. Although adults who were regularly transfused reported worse HRQoL and fatigue compared with those who were not (EuroQol-visual analog scale, 58 vs 80; P = .01), this difference was not seen in children. Regularly transfused adults reported lower physical, emotional, and functional well-being and more anemia symptoms. HRQoL and fatigue significantly differed in children by genotype, with the worst scores in those with 2 severe PKLR mutations; this difference was not seen in adults. However, iron chelation was associated with significantly worse HRQoL scores in children and adults. Pulmonary hypertension was also associated with significantly worse HRQoL. Additionally, 59% of adults and 35% of children reported that their jaundice upset them, identifying this as an important symptom for consideration. Although current treatments for PKD are limited to supportive care, new therapies are in clinical trials. Understanding the impact of PKD on HRQoL is important to assess the utility of these treatments. This trial was registered at www.clinicaltrials.gov as #NCT02053480." @default.
• W3198126629 created "2021-09-13" @default.
• W3198126629 creator A5007020077 @default.
• W3198126629 creator A5011457283 @default.
• W3198126629 creator A5027937488 @default.
• W3198126629 creator A5042897295 @default.
• W3198126629 creator A5052191965 @default.
• W3198126629 creator A5056808711 @default.
• W3198126629 creator A5063350418 @default.
• W3198126629 creator A5064622256 @default.
• W3198126629 creator A5066258828 @default.
• W3198126629 creator A5070471288 @default.
• W3198126629 creator A5075062510 @default.
• W3198126629 creator A5078689579 @default.
• W3198126629 creator A5085331622 @default.
• W3198126629 creator A5090470087 @default.
• W3198126629 date "2022-03-16" @default.
• W3198126629 modified "2023-10-01" @default.
• W3198126629 title "Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency" @default.
• W3198126629 cites W1507052248 @default.
• W3198126629 cites W1608040173 @default.
• W3198126629 cites W1694947395 @default.
• W3198126629 cites W1977762159 @default.
• W3198126629 cites W1983771555 @default.
• W3198126629 cites W2004232121 @default.
• W3198126629 cites W2020114246 @default.
• W3198126629 cites W2036738982 @default.
• W3198126629 cites W2060920389 @default.
• W3198126629 cites W2103618423 @default.
• W3198126629 cites W2346751707 @default.
• W3198126629 cites W2413667755 @default.
• W3198126629 cites W2791144604 @default.
• W3198126629 cites W2804988602 @default.
• W3198126629 cites W2810788093 @default.
• W3198126629 cites W2900882436 @default.
• W3198126629 cites W2939678561 @default.
• W3198126629 cites W2963558146 @default.
• W3198126629 cites W2971686951 @default.
• W3198126629 cites W2997945764 @default.
• W3198126629 cites W3006298960 @default.
• W3198126629 cites W3011696612 @default.
• W3198126629 cites W3029104222 @default.
• W3198126629 cites W3039763738 @default.
• W3198126629 cites W3092539349 @default.
• W3198126629 cites W4238298688 @default.
• W3198126629 cites W4243636833 @default.
• W3198126629 doi "https://doi.org/10.1182/bloodadvances.2021004675" @default.
• W3198126629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34470054" @default.
• W3198126629 hasPublicationYear "2022" @default.
• W3198126629 type Work @default.
• W3198126629 sameAs 3198126629 @default.
• W3198126629 citedByCount "9" @default.
• W3198126629 countsByYear W31981266292020 @default.
• W3198126629 countsByYear W31981266292021 @default.
• W3198126629 countsByYear W31981266292022 @default.
• W3198126629 countsByYear W31981266292023 @default.
• W3198126629 crossrefType "journal-article" @default.
• W3198126629 hasAuthorship W3198126629A5007020077 @default.
• W3198126629 hasAuthorship W3198126629A5011457283 @default.
• W3198126629 hasAuthorship W3198126629A5027937488 @default.
• W3198126629 hasAuthorship W3198126629A5042897295 @default.
• W3198126629 hasAuthorship W3198126629A5052191965 @default.
• W3198126629 hasAuthorship W3198126629A5056808711 @default.
• W3198126629 hasAuthorship W3198126629A5063350418 @default.
• W3198126629 hasAuthorship W3198126629A5064622256 @default.
• W3198126629 hasAuthorship W3198126629A5066258828 @default.
• W3198126629 hasAuthorship W3198126629A5070471288 @default.
• W3198126629 hasAuthorship W3198126629A5075062510 @default.
• W3198126629 hasAuthorship W3198126629A5078689579 @default.
• W3198126629 hasAuthorship W3198126629A5085331622 @default.
• W3198126629 hasAuthorship W3198126629A5090470087 @default.
• W3198126629 hasBestOaLocation W31981266291 @default.
• W3198126629 hasConcept C126322002 @default.
• W3198126629 hasConcept C159110408 @default.
• W3198126629 hasConcept C1862650 @default.
• W3198126629 hasConcept C187212893 @default.
• W3198126629 hasConcept C188816634 @default.
• W3198126629 hasConcept C2778248108 @default.
• W3198126629 hasConcept C2779134260 @default.
• W3198126629 hasConcept C2779951463 @default.
• W3198126629 hasConcept C71924100 @default.
• W3198126629 hasConceptScore W3198126629C126322002 @default.
• W3198126629 hasConceptScore W3198126629C159110408 @default.
• W3198126629 hasConceptScore W3198126629C1862650 @default.
• W3198126629 hasConceptScore W3198126629C187212893 @default.
• W3198126629 hasConceptScore W3198126629C188816634 @default.
• W3198126629 hasConceptScore W3198126629C2778248108 @default.
• W3198126629 hasConceptScore W3198126629C2779134260 @default.
• W3198126629 hasConceptScore W3198126629C2779951463 @default.
• W3198126629 hasConceptScore W3198126629C71924100 @default.
• W3198126629 hasIssue "6" @default.
• W3198126629 hasLocation W31981266291 @default.
• W3198126629 hasLocation W31981266292 @default.
• W3198126629 hasLocation W31981266293 @default.
• W3198126629 hasOpenAccess W3198126629 @default.
• W3198126629 hasPrimaryLocation W31981266291 @default.
• W3198126629 hasRelatedWork W2055141553 @default.
• W3198126629 hasRelatedWork W2076993109 @default.

• next